What Does the Cardiologist Need to Know About SGLT2 Inhibitors?

Published: 25 August 2020

  • Views:

    Views Icon 545
  • Likes:

    Heart Icon 0

Overview

Full programme

  • Views:

    Views Icon 545
  • Likes:

    Heart Icon 0

Overview

In this Educational Symposium from the e-SPACE Heart Failure Global Web-Conference, John McMurray, Mikhail Kosiborod and Avivit Cahn discuss historical data demonstrating the efficacy of SGLT2 inhibitors in HF patients with T2DM, look at data on the use of the agents in non-diabetics and other populations with HFrEF in regards to the DAPA-HF study; and assess how SGLT2 inhibitors should be incorporated within the context of existing therapies in the HFrEF landscape.

 

Organised by the University of Glasgow. Funded by an unrestricted educational grant from AstraZeneca.

Education Objectives

  • Revisit or Enhance Awareness of Historical Data Demonstrating the Efficacy of sglt2 Inhibitors With Regards to Hf Outcomes in Type 2 Diabetes Populations
  • Explore the Recent Emergence of the SGLT2 Inhibitor Class in Non-Diabetes HF Populations and the Clinical Effects of Dapagliflozin Across a Broad Range of Patients With HF With Reduced Ejection Fraction (HfrEF) From the DAPA-HF Trial
  • Strengthen Understanding of How to Use SGLT2 Inhibitors Safely and Effectively in HfrEF, and Within the Context of Existing Therapies in the HFrEF Landscape

Series overview

Part 1

Welcome & Introductions

1 session

Part 2

SGLT2 in Prevention of Heart Failure

1 session

  • SGLT2 in Prevention of Heart Failure

    Watch now

Part 3

DAPA-HF ‘Deep Dive’

1 session

Part 4

Panel Discussion

1 session

Faculty biographies